Regional brain glucose metabolism is differentially affected by ketogenic diet: a human semiquantitative positron emission tomography. 2023

Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
APHM, CNRS, Centrale Marseille, Institut Fresnel, AP-HM, La Timone Hospital, CERIMED, Nuclear Medicine Department, Aix Marseille Univ, Marseille, France. tatiana.horowitz@ap-hm.fr.

Ketogenic diet (KD) is recommended to avoid intense [18F]FDG myocardial physiologic uptake in PET imaging. Neuroprotective and anti-seizure effects of KD have been suggested, but their mechanisms remain to be elucidated. This [18F]FDG PET study aims to evaluate the effect of KD on glucose brain metabolism. Subjects who underwent KD prior to whole-body and brain [18F]FDG PET between January 2019 and December 2020 in our department for suspected endocarditis were retrospectively included. Myocardial glucose suppression (MGS) on whole-body PET was analyzed. Patients with brain abnormalities were excluded. Thirty-four subjects with MGS (mean age: 61.8 ± 17.2 years) were included in the KD population, and 14 subjects without MGS were considered for a partial KD group (mean age: 62.3 ± 15.1 years). Brain SUVmax was first compared between these two KD groups to determine possible global uptake difference. Semiquantitative voxel-based intergroup analyses were secondarily performed to determine possible inter-regional differences by comparing KD groups with and without MGS, separately, to 27 healthy subjects fasting for at least 6 h (mean age of 62.4 ± 10.9 years), and KD groups between them (p-voxel < 0.001, and p-cluster < 0.05, FWE-corrected). A 20% lower brain SUVmax was found in subjects under KD with MGS in comparison to those without MGS (Student's t-test, p = 0.02). Whole-brain voxel-based intergroup analysis revealed that patients under KD with and without MGS had relative hypermetabolism of limbic regions including medial temporal cortices and cerebellum lobes and relative hypometabolism of bilateral posterior regions (occipital), without significant difference between them. KD globally reduces brain glucose metabolism but with regional differences, requiring special attention to clinical interpretation. On a pathophysiological perspective, these findings could help understand underlying neurological effects of KD through possible decrease of oxidative stress in posterior regions and functional compensation in the limbic regions.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D049268 Positron-Emission Tomography An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower. PET Imaging,PET Scan,Positron-Emission Tomography Imaging,Tomography, Positron-Emission,Imaging, PET,Imaging, Positron-Emission Tomography,PET Imagings,PET Scans,Positron Emission Tomography,Positron Emission Tomography Imaging,Positron-Emission Tomography Imagings,Scan, PET,Tomography Imaging, Positron-Emission,Tomography, Positron Emission
D055423 Diet, Ketogenic A course of food intake that is high in FATS and low in CARBOHYDRATES. This diet provides sufficient PROTEINS for growth but insufficient amount of carbohydrates for the energy needs of the body. A ketogenic diet generates 80-90% of caloric requirements from fats and the remainder from proteins. Ketogenic Diet,Diets, Ketogenic,Ketogenic Diets
D019788 Fluorodeoxyglucose F18 The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162) 18F Fluorodeoxyglucose,18FDG,2-Fluoro-2-deoxy-D-glucose,2-Fluoro-2-deoxyglucose,Fludeoxyglucose F 18,18F-FDG,Fluorine-18-fluorodeoxyglucose,Fluorodeoxyglucose F 18,2 Fluoro 2 deoxy D glucose,2 Fluoro 2 deoxyglucose,F 18, Fludeoxyglucose,F 18, Fluorodeoxyglucose,F18, Fluorodeoxyglucose,Fluorine 18 fluorodeoxyglucose,Fluorodeoxyglucose, 18F

Related Publications

Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
March 2006, Neuroscience letters,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
January 1986, Seminars in nuclear medicine,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
May 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
August 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
January 1987, Biological psychiatry,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
April 1983, Developmental medicine and child neurology,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
February 1993, Journal of abnormal psychology,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
January 1999, The International journal of eating disorders,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
August 1988, Pediatric research,
Tatiana Horowitz, and Emilie Doche, and Mary Philip, and Serge Cammilleri, and Laurent Suissa, and Eric Guedj
April 1988, Journal of thoracic imaging,
Copied contents to your clipboard!